Bright Minds says FDA places partial clinical hold on IND and planned U.S. Phase 2

 

Bright Minds says FDA places partial clinical hold on IND and planned U.S. Phase 2 trial of BMB-101 for developmental and epileptic encephalopathies

• FDA cited mouse toxicity findings and insufficient pediatric pharmacokinetic and toxicity data in imposing the partial hold.

https://finviz.com/stock?t=DRUG&p=d